UroGen Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

LSE:0XOD Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
18 Mar 24SellUS$168,600Mark SchoenbergIndividual12,000US$14.05
01 Feb 24SellUS$78,790Jason SmithIndividual4,993US$15.78
01 Feb 24SellUS$59,790Mark SchoenbergIndividual3,789US$15.78

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 0XOD?
Owner TypeNumber of SharesOwnership Percentage
General Public797,5671.89%
Individual Insiders2,328,0195.52%
Hedge Funds7,523,08817.8%
Institutions31,550,74074.8%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 36.7%.


Top Shareholders

Top 25 shareholders own 80.56% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.97%
RTW Investments, LP
3,787,347US$41.0m6.47%0.6%
8.85%
Adage Capital Management, L.P.
3,735,741US$40.4m13.2%0.07%
5.92%
BlackRock, Inc.
2,497,943US$27.0m13.9%no data
5.46%
Menora Mivtachim Pensions & Gemel Ltd.
2,303,031US$24.9m0%0.12%
5.14%
Morgan Stanley, Investment Banking and Brokerage Investments
2,170,527US$23.5m18.8%no data
4.26%
Cowen Inc,Private Banking and Investment Banking Investments
1,796,589US$19.4m-14.4%0.54%
3.73%
Monograph Capital Partners
1,572,327US$17.0m0%no data
3.67%
Cormorant Asset Management, LP
1,550,000US$16.8m-6.06%0.92%
3.6%
Point72 Asset Management, L.P.
1,520,007US$16.4m-39.1%0.04%
3.55%
Millennium Management LLC
1,499,201US$16.2m29.1%0.01%
3.52%
Pontifax Venture Capital
1,485,168US$16.1m0%16.19%
3.29%
UBS Asset Management AG
1,386,847US$15.0m4.13%no data
3.24%
Moshe Arkin
1,369,315US$14.8m0%no data
2.29%
Jefferies Financial Group Inc.,Asset Management Arm
965,000US$10.4m0%0.17%
2.14%
Silverarc Capital Management, LLC
901,129US$9.8m-18.2%2.3%
1.82%
State Street Global Advisors, Inc.
769,583US$8.3m5.9%no data
1.8%
Great Point Partners, LLC
758,786US$8.2m-73.9%3.18%
1.63%
Migdal Mutual Funds Ltd.
686,472US$7.4m0%0.06%
1.32%
Medical Strategy GmbH, Asset Management Arm
555,223US$6.0m0%0.37%
1.17%
Wildcat Capital Management, LLC
495,606US$5.4m0%2.33%
1.1%
Harel Insurance Investments and Finances Services Ltd, Asset Management Arm
463,267US$5.0m-0.06%0.05%
1.09%
Dafna Capital Management, LLC
458,915US$5.0m-2.15%1.34%
1.08%
Geode Capital Management, LLC
455,637US$4.9m8.13%no data
0.97%
Arie Belldegrun
408,693US$4.4m0%no data
0.96%
Opaleye Management Inc.
404,100US$4.4m-1.92%0.75%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 12:53
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

UroGen Pharma Ltd. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anita DushyanthBerenberg
Jonathan AschoffB. Riley Wealth
Jason KolbertD. Boral Capital LLC.